Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bapineuzumab in mild to moderate Alzheimer's disease (ApoE4 non-carriers)
NCT00667810Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Jun 2008
- Primary completion
- Oct 2012
- Modality
- Monoclonal Antibodies
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial of bapineuzumab in Alzheimer's disease (AD) (3 arms), sponsored by Pfizer. Primary endpoints: Alzheimer's Disease Assessment Scale-Cognitive Subscale (11 items) at 78 weeks and Disability Assessment for Dementia at 78 weeks. Started Jun 2008; status: terminated.
02
Drugs
bapineuzumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00667810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00667810.